Special Interview with the Author of Journal of Translational Genetics and Genomics - Dr. Angel Aledo-Serrano
On June 29, 2022, the Editorial Office of Journal of Translational Genetics and Genomics (JTGG, Online ISSN: 2578-5281) is pleased to interview Dr. Angel Aledo-Serrano, from Ruber International Hospital, Madrid, Spain. Dr. Angel Aledo-Serrano is a young neurologist with scientific achievements, who is also active in social media (@AledoNeuro) and organizations.
This interview focuses on a review article titled "Developmental and epileptic encephalopathies after negative or inconclusive genetic testing: what is next?" written by Dr. Angel Aledo-Serrano in JTGG on December 15, 2021. The article received widespread attention since it was published and sparked a lot of buzz on social media.
In this interview, Dr. Aledo-Serrano illustrates the advances and limitations of new diagnostic strategies used in developmental and epileptic encephalopathies patients without a known genetic etiology. What’s more, Dr. Aledo-Serrano shares with us his current research in epilepsy genetics and precision medicine, particularly his view of traditional medicine and precision targeted therapies. In addition, we are deeply impressed by Dr. Aledo-Serrano's motivation to provide social support to epileptic encephalopathies patients. He believes that he should go out and understand his patients' world and listen to their hearts as a neuroscientist. Meanwhile, this would lead to new ideas for research.
Dr. Angel Aledo-Serrano is a neurologist who currently practices in department of neurology of Hospital Ruber Internacional (Madrid). His interests focus on neurogenetics and complex epilepsies, both in pediatric and adult patients. Currently he works on genetic epilepsies, specially in developmental and epileptic encephalopathies, with involvement in multiple clinical trials for precision medicine in neurogenetic conditions. Dr. Aledo-Serrano is a member of the European Society of Paediatric Neurology, as well as the Spanish Association of Human Genetics, and is the medical advisor of different patient advocacy groups related to Dravet, CDKL5, SYNGAP1, SCN8A, and many other conditions.
If you are interested in this review article, please click the link to read: https://oaepublish.com/articles/jtgg.2021.40
JTGG will continue to publish more special interview series. We look forward to building a multi-channel exchange and presentation platform for all scholars who publish papers with us.
Respectfully Submitted by the Journal Editorial Office
Journal of Translational Genetics and Genomics